Santhera's Raxone slows loss of respiratory function in real-world DMD study

Santhera said long-term treatment with Raxone idebenone reduced the annual rate of decline in percent predicted forced vital capacity (FVC)

Read the full 205 word article

How to gain access

Continue reading with a
two-week free trial.